235 related articles for article (PubMed ID: 26173794)
1. Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.
Lucas AT; Madden AJ; Zamboni WC
Expert Opin Drug Metab Toxicol; 2015; 11(9):1419-33. PubMed ID: 26173794
[TBL] [Abstract][Full Text] [Related]
2. The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.
Petschauer JS; Madden AJ; Kirschbrown WP; Song G; Zamboni WC
Nanomedicine (Lond); 2015 Feb; 10(3):447-63. PubMed ID: 25707978
[TBL] [Abstract][Full Text] [Related]
3. Challenges in preclinical to clinical translation for anticancer carrier-mediated agents.
Lucas AT; Madden AJ; Zamboni WC
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Sep; 8(5):642-53. PubMed ID: 26846457
[TBL] [Abstract][Full Text] [Related]
4. Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.
Lucas AT; Price LS; Schorzman A; Zamboni WC
Nanomedicine (Lond); 2017 Aug; 12(16):2021-2042. PubMed ID: 28745129
[TBL] [Abstract][Full Text] [Related]
5. Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents.
Schorzman AN; Lucas AT; Kagel JR; Zamboni WC
Methods Mol Biol; 2018; 1831():201-228. PubMed ID: 30051434
[TBL] [Abstract][Full Text] [Related]
6. Factors Affecting the Pharmacology of Antibody-Drug Conjugates.
Lucas AT; Price LSL; Schorzman AN; Storrie M; Piscitelli JA; Razo J; Zamboni WC
Antibodies (Basel); 2018 Feb; 7(1):. PubMed ID: 31544862
[TBL] [Abstract][Full Text] [Related]
7. Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.
Caron WP; Song G; Kumar P; Rawal S; Zamboni WC
Clin Pharmacol Ther; 2012 May; 91(5):802-12. PubMed ID: 22472987
[TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
9. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics.
Reddy LH; Bazile D
Adv Drug Deliv Rev; 2014 May; 71():34-57. PubMed ID: 24184489
[TBL] [Abstract][Full Text] [Related]
10. Concept and clinical evaluation of carrier-mediated anticancer agents.
Zamboni WC
Oncologist; 2008 Mar; 13(3):248-60. PubMed ID: 18378535
[TBL] [Abstract][Full Text] [Related]
11. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin S; Nehoff H; Greish K
J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
[TBL] [Abstract][Full Text] [Related]
12. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle technologies for cancer therapy.
Alexis F; Pridgen EM; Langer R; Farokhzad OC
Handb Exp Pharmacol; 2010; (197):55-86. PubMed ID: 20217526
[TBL] [Abstract][Full Text] [Related]
14. Liposomal drug formulations in cancer therapy: 15 years along the road.
Slingerland M; Guchelaar HJ; Gelderblom H
Drug Discov Today; 2012 Feb; 17(3-4):160-6. PubMed ID: 21983329
[TBL] [Abstract][Full Text] [Related]
15. Mathematical modeling analysis of intratumoral disposition of anticancer agents and drug delivery systems.
Popilski H; Stepensky D
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):767-84. PubMed ID: 25813659
[TBL] [Abstract][Full Text] [Related]
16. Passive and active drug targeting: drug delivery to tumors as an example.
Torchilin VP
Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
[TBL] [Abstract][Full Text] [Related]
17. Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems.
Piscatelli JA; Ban J; Lucas AT; Zamboni WC
Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33477395
[TBL] [Abstract][Full Text] [Related]
18. Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.
Marchal S; El Hor A; Millard M; Gillon V; Bezdetnaya L
Drugs; 2015 Sep; 75(14):1601-11. PubMed ID: 26323338
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles as delivery carriers for anticancer prodrugs.
Fang JY; Al-Suwayeh SA
Expert Opin Drug Deliv; 2012 Jun; 9(6):657-69. PubMed ID: 22507134
[TBL] [Abstract][Full Text] [Related]
20. Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer.
Gupta P; Jani KA; Yang DH; Sadoqi M; Squillante E; Chen ZS
Expert Opin Drug Metab Toxicol; 2016; 12(3):281-9. PubMed ID: 26799671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
